A nonbile acid farnesoid X receptor agonist tropifexor potently inhibits cholestatic liver injury and fibrosis by modulating the gut-liver axis.
Yongtao XiaoYing WangYang LiuWeipeng WangXinbei TianShanshan ChenYing LuJun DuWei CaiPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
TXR potently ameliorated cholestatic liver injury and fibrosis by modulating the gut-liver axis in piglets. It supports the clinical evaluation of TXR as a therapeutic strategy for cholestatic liver diseases, such as biliary atresia.